Insulin trafficking in a glucose responsive engineered human liver cell line is regulated by the interaction of ATP-sensitive potassium channels and voltage- gated calcium channels

Simpson, AM; Swan, MA; Liu, GJ; Tao, CZ; O'Brien, B; Ch'ng, E; Castro, LM; Ting, HJ; Elgundi, Z; An, T; Lutherborrow, M; Torpy, FR; Martin, DK; Tuch, BE; Nicholson, GM

Insulin trafficking in a glucose responsive engineered human liver cell line is regulated by the interaction of ATP-sensitive potassium channels and voltage- gated calcium channels

Simpson, AM

Swan, MA Liu, GJ Tao, CZ O'Brien, B

Ch'ng, E Castro, LM Ting, HJ Elgundi, Z An, T Lutherborrow, M Torpy, FR

Martin, DK Tuch, BE Nicholson, GM

Permalink

Publisher:: In-Tech
Publication Type:: Chapter
Citation:: Gene Therapy - Tools and Potential Applications, 2013, 1, pp. 703 - 726
Issue Date:: 2013-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download full textAdobe PDF (1.22 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Simpson, AM https://orcid.org/0000-0002-2249-5097	en_US
dc.contributor.author	Swan, MA	en_US
dc.contributor.author	Liu, GJ	en_US
dc.contributor.author	Tao, CZ	en_US
dc.contributor.author	O'Brien, B https://orcid.org/0000-0001-5887-2424	en_US
dc.contributor.author	Ch'ng, E	en_US
dc.contributor.author	Castro, LM	en_US
dc.contributor.author	Ting, HJ	en_US
dc.contributor.author	Elgundi, Z	en_US
dc.contributor.author	An, T	en_US
dc.contributor.author	Lutherborrow, M	en_US
dc.contributor.author	Torpy, FR https://orcid.org/0000-0002-9137-6948	en_US
dc.contributor.author	Martin, DK	en_US
dc.contributor.author	Tuch, BE	en_US
dc.contributor.author	Nicholson, GM	en_US
dc.contributor.editor	Molina, FM	en_US
dc.date.issued	2013-01	en_US
dc.identifier.citation	Gene Therapy - Tools and Potential Applications, 2013, 1, pp. 703 - 726	en_US
dc.identifier.isbn	9789535110149	en_US
dc.identifier.uri	http://hdl.handle.net/10453/27403
dc.description.abstract	Type I diabetes is caused by the autoimmune destruction of pancreatic beta (â) cells [1]. Current treatment requires multiple daily injections of insulin to control blood glucose levels. Tight glucose control lowers, but does not eliminate, the onset of diabetic complications, which greatly reduce the quality and longevity of life for patients. Transplantation of pancreatic tissue as a treatment is restricted by the scarcity of donors and the requirement for lifelong immunosuppression to preserve the graft, which carries adverse side-effects. This is of particular concern as Type 1 diabetes predominantly affects children. Lack of glucose control could be overcome by genetically engineering "an artificial â-cell" that is capable of synthesising, storing and secreting insulin in response to metabolic signals. The donor cell type must be readily accessible and capable of being engineered to synthesise, process, store and secrete insulin under physiological conditions.	en_US
dc.publisher	In-Tech	en_US
dc.relation.ispartof	Gene Therapy - Tools and Potential Applications	en_US
dc.relation.isbasedon	10.5772/52839	en_US
dc.title	Insulin trafficking in a glucose responsive engineered human liver cell line is regulated by the interaction of ATP-sensitive potassium channels and voltage- gated calcium channels	en_US
dc.type	Chapter
utslib.location	Rijeka, Croatia	en_US
utslib.for	100401 Gene and Molecular Therapy	en_US
utslib.for	0601 Biochemistry and Cell Biology	en_US
utslib.citation.edition	1	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Medical and Molecular Sciences
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
utslib.copyright.status	open_access
pubs.consider-herdc	true	en_US
pubs.edition	1	en_US
pubs.place-of-publication	Rijeka, Croatia	en_US
pubs.publication-status	Published	en_US

Abstract:

Type I diabetes is caused by the autoimmune destruction of pancreatic beta (â) cells [1]. Current treatment requires multiple daily injections of insulin to control blood glucose levels. Tight glucose control lowers, but does not eliminate, the onset of diabetic complications, which greatly reduce the quality and longevity of life for patients. Transplantation of pancreatic tissue as a treatment is restricted by the scarcity of donors and the requirement for lifelong immunosuppression to preserve the graft, which carries adverse side-effects. This is of particular concern as Type 1 diabetes predominantly affects children. Lack of glucose control could be overcome by genetically engineering "an artificial â-cell" that is capable of synthesising, storing and secreting insulin in response to metabolic signals. The donor cell type must be readily accessible and capable of being engineered to synthesise, process, store and secrete insulin under physiological conditions.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/27403